3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
5
Completed
5
Recruiting
2
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neuroblastoma
3
Melanoma
3
Uterine Cervical Neoplasms
2
Nasopharyngeal Carcinoma
2
Lymphoma, Non-Hodgkin
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Stomach Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Anus Neoplasms
1
Advanced Refractory Solid Tumors
1
Advanced Malignant Solid Tumor
1
Interventions
Cyclophosphamide
17
fludarabine
13
Dexamethasone
12
Cisplatin
11
Rituximab
10
Gemcitabine
9
Paclitaxel
7
Lenalidomide
7
Decitabine
7
Cytarabine
7
Bendamustine Hydrochloride
7
fludarabine phosphate
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Etoposide
6
Carboplatin
6
Bortezomib
6
Radiotherapy
5
Injections
5
Azacitidine
5
camrelizumab
4
apatinib
4
Valproic Acid
4
Thalidomide
4
Procarbazine
4
Oxaliplatin
4
Drug Therapy
4
Antilymphocyte Serum
4
tislelizumab
3
pomalidomide
3
liposomal doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Recurrence
×
Interleukin-2
×
Clear all
NCT05895370
2023-06-08
GI-HPVT-01
BGI, China
Phase 1
Unknown
12 enrolled